Glucose Control Therapies

FacebookTwitterEmail
 

This resource on Type 1 Diabetes Research was created in partnership with JDRF through the JDRF – Beyond Type 1 Alliance.


 

Finding simpler and more advanced ways to help people living with Type 1 Diabetes control their glucose levels is one of the best ways to improve lives today. With recent advances in technology, approval of hybrid-closed loop systems, and new drug classes being investigated, there has never been a better time to have diabetes. Glucose control therapy research focuses three core areas:

  • Artificial pancreas (AP) technologies such as the recently approved Control-IQ from Tandem Diabetes Care
  • Next-generation insulin classes such as ultra-fast insulin, and “smart” insulin that can automatically react to the changes in the blood glucose levels
  • Investigation into other drug classes such as SGLT inhibitors to improve blood glucose management

Helping people with T1D manage their glucose levels not only lowers the risk for future complications, it makes every day easier to get through without constantly worrying about your numbers!

Glucose Control Therapies: The Latest News

vTv Therapeutics Announces Positive Study Results of Potential First-in-Class Oral Adjunctive Therapy for T1D


On February 10, vTv Therapeutics announced positive study results from the second part of the Phase 2 Simplici-T1 Study of TTP399.READ MORE

JDRF CEO to Health Insurers: Cover New Technology


JDRF President & CEO Aaron Kowalski, Ph.D calls on insurers to cover FDA approved type 1 diabetes technologyREAD MORE

Tandem’s Control-IQ Hybrid Closed Loop Approved by the FDA


The FDA announced the approval of the Control-IQ Hybrid Closed Loop System from Tandem Diabetes Care. The system sees the t:slim X2 insulin pump and Dexcom G6 continuous glucose monitor working together with help from Control-IQ's groundbreaking algorithm.READ MORE

Exciting Trial Results for Tandem’s Control-IQ Hybrid Closed Loop System


Participants using Control-IQ saw an increased time in range, lowered HbA1c, and less time in hyperglycemia and hypoglycemia.READ MORE

Tidepool and Medtronic Announce Collaboration on Interoperable Automated Insulin Pump


Tidepool announced that they have partnered with Medtronic to create an interoperable automated insulin pump system.READ MORE

European Commission Approves Zynquista, First Dual SGLT Inhibitor for T1D


Zynquista is the first dual SGLT1 and SGLT2 inhibitor approved for use in Type 1 diabetes, and the second oral medication approved for use in Type 1 diabetes. READ MORE

Glucose Control Therapies: Trials

 


To learn more about all the great T1D research being funded by JDRF, visit their research and impact page here.